m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG03094)
Name
TWS-119
Synonyms
TWS119; 601514-19-6; TWS-119; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB
    Click to Show/Hide
Status
Investigative
Structure
Formula
C18H14N4O2
InChI
1S/C18H14N4O2/c19-12-4-1-3-11(7-12)16-9-15-17(22-16)20-10-21-18(15)24-14-6-2-5-13(23)8-14/h1-10,23H,19H2,(H,20,21,22)
InChIKey
VPVLEBIVXZSOMQ-UHFFFAOYSA-N
PubChem CID
9549289
TTD Drug ID
D0T8KR
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Glycogen synthase kinase-3 beta (GSK-3B)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for TWS-119. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of TWS-119 through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). [1], [2]
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for TWS-119. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of TWS-119 through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). [2], [3]
Proto-oncogene c-Myc (MYC)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Proto-oncogene c-Myc (MYC) is a therapeutic target for TWS-119. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of TWS-119 through regulating the expression of Proto-oncogene c-Myc (MYC). [4], [5]
Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Proto-oncogene c-Myc (MYC) is a therapeutic target for TWS-119. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of TWS-119 through regulating the expression of Proto-oncogene c-Myc (MYC). [5], [6]
Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Proto-oncogene c-Myc (MYC) is a therapeutic target for TWS-119. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of TWS-119 through regulating the expression of Proto-oncogene c-Myc (MYC). [5], [7]
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Proto-oncogene c-Myc (MYC) is a therapeutic target for TWS-119. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of TWS-119 through regulating the expression of Proto-oncogene c-Myc (MYC). [5], [8]
Insulin-like growth factor-binding protein 3 (IGFBP3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Proto-oncogene c-Myc (MYC) is a therapeutic target for TWS-119. The Insulin-like growth factor-binding protein 3 (IGFBP3) has potential in affecting the response of TWS-119 through regulating the expression of Proto-oncogene c-Myc (MYC). [5], [8]
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Proto-oncogene c-Myc (MYC) is a therapeutic target for TWS-119. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of TWS-119 through regulating the expression of Proto-oncogene c-Myc (MYC). [5], [9]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Proto-oncogene c-Myc (MYC) is a therapeutic target for TWS-119. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of TWS-119 through regulating the expression of Proto-oncogene c-Myc (MYC). [4], [5]
Methyltransferase-like 5 (METTL5)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Proto-oncogene c-Myc (MYC) is a therapeutic target for TWS-119. The Methyltransferase-like 5 (METTL5) has potential in affecting the response of TWS-119 through regulating the expression of Proto-oncogene c-Myc (MYC). [5], [10]
Wilms tumor 1-associating protein (WTAP)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Proto-oncogene c-Myc (MYC) is a therapeutic target for TWS-119. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of TWS-119 through regulating the expression of Proto-oncogene c-Myc (MYC). [5], [11]
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Proto-oncogene c-Myc (MYC) is a therapeutic target for TWS-119. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of TWS-119 through regulating the expression of Proto-oncogene c-Myc (MYC). [4], [5]
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Proto-oncogene c-Myc (MYC) is a therapeutic target for TWS-119. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of TWS-119 through regulating the expression of Proto-oncogene c-Myc (MYC). [5], [12]
Transcription factor AP-1 (JUN)
Protein virilizer homolog (VIRMA)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Transcription factor AP-1 (JUN) is a therapeutic target for TWS-119. The Protein virilizer homolog (VIRMA) has potential in affecting the response of TWS-119 through regulating the expression of Transcription factor AP-1 (JUN). [13], [14]
References
Ref 1 Vascular Smooth Muscle FTO Promotes Aortic Dissecting Aneurysms via m6A Modification of Klf5. Front Cardiovasc Med. 2020 Nov 20;7:592550. doi: 10.3389/fcvm.2020.592550. eCollection 2020.
Ref 2 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029796)
Ref 3 N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer. Nat Commun. 2022 May 13;13(1):2672. doi: 10.1038/s41467-022-30217-7.
Ref 4 Correlation of m6A methylation with immune infiltrates and poor prognosis in non-small cell lung cancer via a comprehensive analysis of RNA expression profiles. Ann Transl Med. 2021 Sep;9(18):1465. doi: 10.21037/atm-21-4248.
Ref 5 Anti-ageing pipeline starts to mature. Nat Rev Drug Discov. 2018 Sep;17(9):609-612. doi: 10.1038/nrd.2018.134. Epub 2018 Aug 3.
Ref 6 N(6)-methyladenosine (m(6)A) reader IGF2BP1 accelerates gastric cancer aerobic glycolysis in c-Myc-dependent manner. Exp Cell Res. 2022 Aug 1;417(1):113176. doi: 10.1016/j.yexcr.2022.113176. Epub 2022 Apr 27.
Ref 7 LncRNA-PACERR induces pro-tumour macrophages via interacting with miR-671-3p and m6A-reader IGF2BP2 in pancreatic ductal adenocarcinoma. J Hematol Oncol. 2022 May 7;15(1):52. doi: 10.1186/s13045-022-01272-w.
Ref 8 The RNA m6A Reader YTHDF2 Maintains Oncogene Expression and Is a Targetable Dependency in Glioblastoma Stem Cells. Cancer Discov. 2021 Feb;11(2):480-499. doi: 10.1158/2159-8290.CD-20-0331. Epub 2020 Oct 6.
Ref 9 Recognition of RNA N(6)-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat Cell Biol. 2018 Mar;20(3):285-295. doi: 10.1038/s41556-018-0045-z. Epub 2018 Feb 23.
Ref 10 Ribosome 18S m(6)A methyltransferase METTL5 promotes pancreatic cancer progression by modulating c?Myc translation. Int J Oncol. 2022 Jan;60(1):9. doi: 10.3892/ijo.2021.5299. Epub 2021 Dec 31.
Ref 11 High Wilms' tumor 1 associating protein expression predicts poor prognosis in acute myeloid leukemia and regulates m(6)A methylation of MYC mRNA. J Cancer Res Clin Oncol. 2021 Jan;147(1):33-47. doi: 10.1007/s00432-020-03373-w. Epub 2020 Sep 3.
Ref 12 Inhibition of YTHDF2 triggers proteotoxic cell death in MYC-driven breast cancer. Mol Cell. 2021 Aug 5;81(15):3048-3064.e9. doi: 10.1016/j.molcel.2021.06.014. Epub 2021 Jul 2.
Ref 13 KIAA1429 regulates cell proliferation by targeting c-Jun messenger RNA directly in gastric cancer. J Cell Physiol. 2020 Oct;235(10):7420-7432. doi: 10.1002/jcp.29645. Epub 2020 Feb 13.
Ref 14 CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.